Neuro-Sys is both a CRO and a drug discovery company focused on neurodegenerative diseases.
Mode of action study of NSP01-E, a potential treatment for Alzheimer’s disease, in protection against amyloid β peptide (Aβ) injury.
Link to poster
2016, September 29-30
Meet us @ booth 13
Link to event
Model of BBB to assess the BBB penetrance of molecule in the CNS.
Under healthy condition or pathological conditions (AD, PD or stress conditions).
Contact us for more information
As a CRO, the Neuro-Sys’ NS-SERVICES department provides the pharmaceutical and biotech industry with efficient and highly skilled preclinical modeling services. With a strong expertize and cutting-edge laboratory equipment, Neuro-Sys develops and uses specific preclinical models of CNS diseases to achieve high-quality efficacy pharmacology and mode of action studies.
We are dedicated to provide high-level technical expertise and preclinical CRO services in a collaborative relationship with our clients, mainly focusing on:
- Alzheimer disease (AD)
- Parkinson disease (PD)
- Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s disease)
Neuro-Sys also provides efficacy testings for food/dietary supplements and medical nutrition that may have an activity on CNS.
Neuro-Sys set up its proper dedicated drug discovery department NS-PHARMA and laboratory to realize in-house R&D programs with finding new compounds coming from specific medicinal plants as a perspective.
Going forward, the brand new compounds with a proven and demonstrated activity on neurological disorders are put on the market for the pharmacological industry, capable to make all the further development.